重复经颅磁刺激(rTMS)减少酒精使用障碍患者饮酒量的疗效(ALCOSTIM):一项随机对照试验的研究方案
ALCOSTIM是一项在法国2个中心开展的随机、双盲、安慰剂对照、平行组试验方案,计划纳入144名18岁以上酒精使用障碍(AUD)患者,随机接受连续5天每日两次活性或假rTMS(右侧背外侧前额叶皮层10 Hz,每天2000脉冲)。主要结局为rTMS结束后4周内饮酒量变化,次要结局包括24周内饮酒量变化、渴求、临床与生物学改善、情绪与生活质量、认知与安全性评估及吸烟者烟草消耗评估。
要点
- rTMS(右侧DLPFC 10 Hz,每天2000脉冲)连续5天每日两次,用于减少AUD患者饮酒量。
- 主要结局为rTMS结束后4周内饮酒量变化,随访至24周。
- 计划纳入144名18岁以上AUD患者,在法国2个中心随机分组。
核心结论
- 研究假设rTMS可减少酒精使用障碍患者的饮酒量,本方案旨在通过大样本随机对照试验评估其疗效。
研究设计与样本
- 随机、双盲、安慰剂对照、平行组试验方案,在法国2个中心开展。
- 计划纳入144名18岁以上诊断为酒精使用障碍的受试者。
- 受试者随机接受连续5天每日两次活性或假rTMS(右侧背外侧前额叶皮层10 Hz,每天2000脉冲)。
主要发现
- 主要结局为rTMS结束后4周内饮酒量变化。
- 次要结局包括24周内饮酒量变化、酒精渴求、临床与生物学改善、情绪与生活质量、认知与安全性评估,以及吸烟者烟草消耗评估。
局限性
- 原文指出迄今尚无研究纳入足够大的样本和足够长的随访来证实rTMS减少饮酒的假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The number of people with an alcohol use disorder (AUD) was recently estimated to be 63.5 million worldwide. The global burden of disease and injury attributable to alcohol is considerable: about 3 million deaths, namely one in 20, were caused by alcohol in 2015. At the same time, AUD remains seriously undertreated. In this context, alternative or adjunctive therapies such as brain stimulation could play an important role. The early results of studies using repetitive transcranial magnetic stimulation (rTMS) suggest that stimulations delivered to the dorsolateral prefrontal cortex significantly reduce cravings and improve decision-making processes in various addictive disorders. We therefore hypothesize that rTMS could lead to a decrease in alcohol consumption in patients with AUD. METHODS/DESIGN: We report the protocol of a randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy of rTMS on alcohol reduction in individuals diagnosed with AUD. The study will be conducted in 2 centers in France. Altogether, 144 subjects older than 18 years and diagnosed with AUD will be randomized to receive 5 consecutive twice-daily sessions of either active or sham rTMS (10 Hz over the right DLPFC, 2000 pulses per day). The main outcomes of the study will be changes in alcohol consumption within the 4 weeks after the rTMS sessions. Secondary outcome measures will include changes in alcohol consumption within the 24 weeks, alcohol cravings, clinical and biological improvements, effects on mood and quality of life, and cognitive and safety assessments, and, for smokers, an assessment of the effects of rTMS on tobacco consumption. DISCUSSION: Several studies have observed a beneficial effect of rTMS on substance use disorders by reducing craving, impulsivity, and risk-taking behavior and suggest that rTMS may be a promising treatment in addiction. However, to date, no studies have included sufficiently large samples and sufficient follow-up to confirm this hypothesis. The results from this large randomized controlled trial will give a better overview of the therapeutic potential of rTMS in AUD. TRIAL REGISTRATION: ClinicalTrials.gov NCT04773691. Registered on 26 February 2021 https://clinicaltrials.gov/ct2/show/NCT04773691?term=trojak&draw=2&rank=5 .
引用
- Petit B, Soudry-Faure A, Jeanjean L, et al. Efficacy of repetitive transcranial magnetic stimulation (rTMS) for reducing consumption in patients with alcohol use disorders (ALCOSTIM): study protocol for a randomized controlled trial. Trials. 2022. PMID: 35022086. doi:10.1186/s13063-021-05940-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。